5663
Iman Mohamed Fikry Ragai
Study of Anti-Apolipoprotein A-I Antibodies and Paraoxonase 1 Activity in Systemic Lupus Erythematosus Patients; Correlation with Disease Activity and Damage Indices.
Systemic lupus erythematosus (SLE), anti- apolipoprotein A-I antibody (anti-Apo A-I) ,paraoxonase 1)PON1).
Systemic lupus erythematosus (SLE) patients have an increased risk of atherosclerosis. Identification of at-risk patients and the pathogenesis of atherosclerosis in SLE remain elusive. Paraoxonase 1 (PON1) and anti- apolipoprotein A-I antibody (anti-Apo A-I) appear to have a potential role in premature atherosclerosis in SLE. The aim of this study was to assess two novel risk factors of atherosclerosis in SLE patients; PON1 activity, anti-Apo A-I antibody levels, to find any possible correlation between both of them, and to demonstrate their relations to disease activity as well as disease related damage.
2019
Ph.d
Cairo
Medicine